Three major classes of opioid receptors, mu(mu), delta (delta) and kappa (kappa), have been defined based on differences in their pharmacology, physiology and tissue distribution. When stimulated in vivo the opioid receptors activate a cascade of intracellular reactions involving adenylyl cyclase, calcium channels and potassium channels, which result in many of the classical effects of opiate intoxication including euphoria, analgesia and physical dependence. The molecular characterization of the opioid receptors has been slow due to several factors, perhaps the most important of which being that they are intrinsic membrane proteins which are difficult to solubilize in active form and they are expressed in relatively low amounts. Recently these difficulties were overcome by the expression cloning of a mouse delta opioid receptor subtype from the neuroblastoma X glioma cell line NG108- 15. The primary known as the G protein-coupled receptors. In light of these recent reports we re-examined the sequence of an orphan receptor clone which we had obtained by degenerate PCR. This cDNA clone, referred to as R21, encodes a novel G protein-coupled receptor which shares significant sequence identity with the recently published mouse delta opioid receptor. Based on the conservation of key amino acid residues and the overall homology between R21 and the mouse delta opioid receptor we predict that R21 is a member of the opioid receptor family. To test this hypothesis we propose to pharmacologically characterize the receptor encoded by R21 and investigate the affect its stimulation has on adenylyl cyclase and a voltage-dependent outwardly rectifying potassium conductance. Once pharmacologically defined the tissue regulated the rat R21 gene will be characterized. The human homologue of the R21 gene will also be characterized to identify markers that can be used i genetic linkage and association studies of HR21 and human disease. Eventually the mouse gene, MR21, will be target and knocked out. These transgenic mice will be a valuable model system in which to evaluate the receptor's role in processes ranging from synaptic transmission to behavior.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA008562-02
Application #
2121101
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1993-12-10
Project End
1996-01-31
Budget Start
1994-12-01
Budget End
1996-01-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
Organized Research Units
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Grandy, David K (2007) Trace amine-associated receptor 1-Family archetype or iconoclast? Pharmacol Ther 116:355-90
Allen, R G; Peng, B; Pellegrino, M J et al. (2001) Altered processing of pro-orphanin FQ/nociceptin and pro-opiomelanocortin-derived peptides in the brains of mice expressing defective prohormone convertase 2. J Neurosci 21:5864-70
Allen, C N; Jiang, Z G; Teshima, K et al. (1999) Orphanin-FQ/nociceptin (OFQ/N) modulates the activity of suprachiasmatic nucleus neurons. J Neurosci 19:2152-60
Slugg, R M; Ronnekleiv, O K; Grandy, D K et al. (1999) Activation of an inwardly rectifying K+ conductance by orphanin-FQ/nociceptin in vasopressin-containing neurons. Neuroendocrinology 69:385-96
Tian, J H; Zhang, W; Fang, Y et al. (1998) Endogenous orphanin FQ: evidence for a role in the modulation of electroacupuncture analgesia and the development of tolerance to analgesia produced by morphine and electroacupuncture. Br J Pharmacol 124:21-6
Wagner, E J; Ronnekleiv, O K; Grandy, D K et al. (1998) The peptide orphanin FQ inhibits beta-endorphin neurons and neurosecretory cells in the hypothalamic arcuate nucleus by activating an inwardly-rectifying K+ conductance. Neuroendocrinology 67:73-82
Quigley, D I; McDougall, J; Darland, T et al. (1998) Orphanin FQ is the major OFQ1-17-containing peptide produced in the rodent and monkey hypothalamus. Peptides 19:133-9
Tian, J H; Xu, W; Fang, Y et al. (1997) Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br J Pharmacol 120:676-80
Morgan, M M; Grisel, J E; Robbins, C S et al. (1997) Antinociception mediated by the periaqueductal gray is attenuated by orphanin FQ. Neuroreport 8:3431-4
Heinricher, M M; McGaraughty, S; Grandy, D K (1997) Circuitry underlying antiopioid actions of orphanin FQ in the rostral ventromedial medulla. J Neurophysiol 78:3351-8

Showing the most recent 10 out of 16 publications